Detalles de la búsqueda
1.
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Clin Cancer Res;
2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38837894
2.
Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Clin Transl Med;
14(4): e1617, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38664548
3.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
J Clin Oncol;
42(18): 2149-2160, 2024 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537155
4.
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project.
Front Oncol;
13: 1247270, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954071
5.
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Clin Cancer Res;
29(17): 3384-3394, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432976
6.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Trials;
24(1): 338, 2023 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37198674
7.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol;
9(7): 946-954, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166817
8.
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
Clin Cancer Res;
29(13): 2456-2465, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37014668
9.
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Int J Mol Sci;
24(3)2023 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36769215
10.
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
BMC Cancer;
22(1): 1040, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195836
11.
Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS).
Breast Care (Basel);
17(5): 508-513, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36684406
12.
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status.
Clin Epigenetics;
13(1): 184, 2021 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602069
13.
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
PLoS One;
16(9): e0257142, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34469495
14.
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
BMC Cancer;
21(1): 1024, 2021 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34526003
15.
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
BMC Cancer;
21(1): 920, 2021 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391399
16.
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Eur J Cancer;
152: 193-203, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34116270
17.
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
Clin Cancer Res;
27(9): 2584-2591, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33593886
18.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol;
22(1): 85-97, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357420
19.
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
J Am Heart Assoc;
9(23): e018143, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191846
20.
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.
J Immunother Cancer;
8(2)2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33199511